Your session is about to expire
← Back to Search
This trial will test if XmAb20717 is safe and effective in treating patients with certain advanced gynecologic or genitourinary cancers.
- Metastatic Castration Resistant Prostate Cancer
- Ovarian Cancer
- Clear Cell Carcinoma
- Endometrial Cancer
- Cervical Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the U.S. Food and Drug Administration granted authorization for XmAb20717?
"Our experts at Power assigned XmAb20717 a score of 2 since there is evidence to suggest its safety, but no clinical results back up its efficacy."
Is enrollment for this trial still available to those seeking treatment?
"According to the data on clinicaltrials.gov, this medical trial is actively seeking participants. It was originally posted on July 21st 2022 and updated most recently on July 19th of that same year."
To what extent is participation in this research project being observed?
"To execute this research, ICON plc needs to acquire 150 suitable patients. The two trial locations are Valkyrie Clinical Trials (Los Angeles) and Comprehensive Cancer Centers of Nevada-Southern Hills (Las Vegas)."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends